BCNU
BCNU Brand names, BCNU Analogs
BCNU Brand Names Mixture
- No information avaliable
BCNU Chemical_Formula
C5H9Cl2N3O2
BCNU RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
BCNU fda sheet
BCNU msds (material safety sheet)
BCNU Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
BCNU Molecular Weight
214.049 g/mol
BCNU Melting Point
31 oC
BCNU H2O Solubility
< 0.1 g/100 mL at 18 °C
BCNU State
Solid
BCNU LogP
1.256
BCNU Dosage Forms
Powder for solution; Wafer
BCNU Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
BCNU Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
BCNU Absorption
5 to 28% bioavailability
BCNU side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
BCNU Patient Information
No information avaliable
BCNU Organisms Affected
Humans and other mammals
